Covidien (NYSE:COV) said Dr. Martin Madaus will step down from its board of directors to take an open CEO position with a privately-owned company.
Covidien taps Quanterix CEO for board | Personnel Moves
Med-tech titan Covidien (NYSE:COV) named Quanterix Corp. CEO Martin Madaus to its board of directors.
Madaus, the former head of Millipore, was tapped by Quanterix in September for the corner office. His nomination, effective Dec. 1, is slated for a shareholder vote next year.
Intrinsic Therapeutics puts a new man in charge | Personnel Moves
Intrinsic Therapeutics named Wright Medical (NSQD:WMGI) veteran Cary Hagan as its new President & CEO. Greg Lambrect, founder of Intrinsic will stay on as executive director.
"Cary’s proven success in bringing new technologies to the global market makes him an ideal choice to lead Intrinsic’s next stage of growth as we expand our international clinical and commercial activity," said Lambrecht in prepared remarks.
Dr. Martin Madaus joins Quanterix as CEO
Former CEO of Millipore Brings Extensive Commercial Expertise to New Role
Tissue Genesis starts trial on vascular grafts with fat-derived stem cells | Research roundup
Tissue Genesis Inc. began clinical trials for a peripheral vascular disease (PVD) treatment composed of adipose-derived adult stem cell-coated vascular grafts. Adipose is more commonly know as fat, a tissue that the company believes has high-output regenerative medicine potential.
The Honolulu-based Tissue Genesis is the first to initiate an FDA-approved trial using the patient’s own fat-derived adult stem cells (ASCs) prepared at the point-of-care, according the company company.
Glenveigh lands deal for Monica Healthcare’s new fetal monitor | Distribution roundup
Here’s a roundup of companies announcing new distribution deals.
MassDevice Network
@MassDevice
LinkedIn
YouTube